Hims & Hers rebounded by 11.76 percent on Thursday to close at $46.28 apiece amid reaffirmations to continue offering cheaper ...

Gain 2x leveraged exposure to HIMS with HIMZ, ideal for high-risk traders. Read more on how to navigate recent volatility and ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Regional bank Provident Financial Services (NYSE:PFS) rose by 5.8% on Thursday after Raymond James initiated coverage on the ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

The collaboration, set to begin on 1 July, will see Novo Nordisk team up with the telehealth company to offer Wegovy to ...

I’m in London, and I just paid for this damn fat drug I take. I said, it’s not working. They said, he said, I just paid $88 ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. Under the deal, cash-paying patients can access a month's supply ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.